Erasca/$ERAS
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Erasca
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its focused RAS/MAPK pathway pipeline comprises modality-agnostic programs aligned with three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes two clinical-stage programs (ERAS-0015, a pan-RAS molecular glue; and ERAS-4001, a pan-KRAS inhibitor), and ERAS-12, a discovery-stage program.
Ticker
$ERAS
Sector
Primary listing
Employees
103
Headquarters
Website
Erasca Metrics
BasicAdvanced
$4.7B
-
-$0.44
1.17
-
Price and volume
Market cap
$4.7B
Beta
1.17
52-week high
$16.41
52-week low
$1.01
Average daily volume
4.4M
Financial strength
Current ratio
10.04
Quick ratio
9.771
Long term debt to equity
12.939
Total debt to equity
14.497
Profitability
EBITDA (TTM)
-128.298
Management effectiveness
Return on assets (TTM)
-18.28%
Return on equity (TTM)
-33.27%
Valuation
Price to book
13.34
Price to tangible book (TTM)
13.34
Price to free cash flow (TTM)
-41.174
Free cash flow yield (TTM)
-2.43%
Free cash flow per share (TTM)
-0.371
Growth
Earnings per share change (TTM)
-36.46%
3-year earnings per share growth (CAGR)
-39.56%
What the Analysts think about Erasca
Analyst ratings (Buy, Hold, Sell) for Erasca stock.
Erasca Financial Performance
Revenues and expenses
Erasca Earnings Performance
Company profitability
Erasca News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Erasca stock?
Erasca (ERAS) has a market cap of $4.7B as of March 20, 2026.
What is the P/E ratio for Erasca stock?
The price to earnings (P/E) ratio for Erasca (ERAS) stock is 0 as of March 20, 2026.
Does Erasca stock pay dividends?
No, Erasca (ERAS) stock does not pay dividends to its shareholders as of March 20, 2026.
When is the next Erasca dividend payment date?
Erasca (ERAS) stock does not pay dividends to its shareholders.
What is the beta indicator for Erasca?
Erasca (ERAS) has a beta rating of 1.17. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.